
Pfizer, Merck KGaA hit the brakes on another PhIII as PD-L1 Bavencio flops yet again
Pfizer and Merck KGaA are cementing in their distant runner-up status for Bavencio (avelumab), a PD-L1 checkpoint that just failed its fourth late-stage trial. And the drumbeat of setbacks — at a time checkpoints are proliferating around the world — will hurt their prospects for making this the blockbuster they both need.
This time around researchers simply said that Bavencio in combination with or following chemo in frontline ovarian cancer cases had failed the primary endpoint on progression-free survival, forcing them to draw a halt to the work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.